Prot #WO29636: A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) versus Observation as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Urothelial Carcinoma after Surgical Resection

Project: Research project

Project Details

StatusFinished
Effective start/end date1/10/17 → 1/10/23

Funding

  • INC Research, LLC (Prot #WO29636)
  • Genentech, Inc. (Prot #WO29636)